Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Jun 30,2021
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Recently, the orphan drug KBMAB-16 (intravenous injection of tumor necrosis factor-α inhibitor), a major project of a well-known Chinese pharmaceutical company located in Chengdu, was successfully approved for clinical trial application (IND) by the US Food and Drug Administration (US FDA).
More
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Jun 25,2021
Medicilon's "New Drugs + AI Innov Forum" was successful held
When AI accurately predicts the "difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism
More
Medicilon's "New Drugs + AI Innov Forum" was successful held
Jun 08,2021
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use.
More
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
May 14,2021
Safety assessment lab of process chemistry
Safety assessment lab of process chemistry In the research and development process of innovative drugs, the chemical process research of drugs plays a pivotal role. 
More
Safety assessment lab of process chemistry
May 01,2021
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
On July 15, 2021, Vastpro and Medicilon signed a strategic cooperation agreement in the Medicilon Chuansha Park to reach a long-term strategic cooperation relationship.Vastpro president
More
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
Apr 25,2021
Medicilon Appoints Two Vice Presidents
Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president
More
Medicilon Appoints Two Vice Presidents
Apr 21,2021
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for
More
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Apr 08,2021
Medicilon will participate 2021 AACR Virtual Annual Meeting
#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical
More
Medicilon will participate 2021 AACR Virtual Annual Meeting
Mar 29,2021
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
More
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Mar 08,2021
Medicilon will participate 2021 SOT Virtual Annual Meeting
Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr.
More
Medicilon will participate 2021 SOT Virtual Annual Meeting
Feb 25,2021
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
On February 22, 2021, Nanjing TransThera Biosciences Co., Ltd. ("TransThera”) and the life science company of South Korea's LG Chem ("LG Chem”) jointly announced the
More
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
Feb 10,2021
Happy Chinese New Year
Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness
More
Happy Chinese New Year